InvestorsHub Logo
Followers 7
Posts 1173
Boards Moderated 0
Alias Born 11/13/2018

Re: Biobillionair post# 212646

Wednesday, 09/04/2019 7:30:12 PM

Wednesday, September 04, 2019 7:30:12 PM

Post# of 425596
I don't think they are killing but they are definitely not helping. The FDA wanted proof and now they have it and they are being slow to act on it. Typical government bureaucracy. I think they have created in inequity where those who are aware of Vascepa and can afford it are getting it and those who can't are left in the dark.

The AHA also seems to be more political than I would have thought. JT said today "European Society of Cardiology, is trying to ensure that they are at the forefront of cardiovascular medicine, not just for Europe but globally. And they saw that the incorporation of icosapent ethyl which is Vascepa in their guidelines make sense for treatment of patients. And what they were looking for and recommended in their guidelines is that Vascepa be considered for treatment of patients who despite statin treatment had elevated triglycerides." That to me is aimed at the AHA who have a long way to go with their next updated guideline.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News